Luminex

Luminex Corporation develops, manufactures, and sells biological testing technologies and products with applications throughout the life sciences and diagnostics industries. The Company's Multi-Analyte Profiling (xMAP) technology, an open architecture, multiplexing technology, allows simultaneous analysis of up to 500 bioassays from a small sample volume, a single drop of fluid, by reading biological tests on the surface of microscopic polystyrene beads called microspheres. xMAP technology combines this miniaturized liquid array bioassay capability with small lasers, digital signal processors, and software. The Company operates in two segments the technology and strategic partnerships (TSP) segment, and the assays and related products (ARP) segment.

AUSTIN, Texas, May 20, 2021 /PRNewswire/ -- Luminex Corporation (Nasdaq:LMNX) (the "Company") today announced that its board of directors declared a cash dividend for the second quarter of 2021 of $0.10 per share of common stock payable on July 8, 2021 to stockholders of record as of the close of business June 17, 2021. About Luminex Corporation At Luminex, our mission is to empower labs to obtain reliable, timely, and actionable answers, ultimately advancing health.

Luminex Corporation Declares Second Quarter Cash Dividend

DiaSorin is a world leader in the sale of reagents to laboratories. It converts about 25-30% of its revenue into free cash flow.

DiaSorin: Surfing The COVID-19 Wave, Culminating In A $1.8 Billion Acquisition Of Luminex

NEW YORK, April 16, 2021 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating Luminex Corp. ("LMNX" or the "Company") ( LMNX ) relating to its proposed acquisition by DiaSorin S.p.A. Under the terms of the agreement, LMNX shareholders will receive $37.00 in cash per share.

SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Luminex Corp. - LMNX

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Luminex Corporation (NasdaqGS: LMNX) to DiaSorin S.p.A. (OTC: DSRLF). Under the terms of the proposed transaction, shareholders of Luminex will receive only $37.00 in cash for each share of Luminex that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate

LUMINEX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Luminex Corporation - LMNX

Luminex (LMNX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Strength Seen in Luminex (LMNX): Can Its 12.4% Jump Turn into More Strength?

Cadence Bank

GenMark Diagnostics

Nuance Communications

NEW YORK, April 13, 2021 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Luminex Corporation (NASDAQ: LMNX)  concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to DiaSorin S.p.A. for $37.00 per share.

INVESTIGATION ALERT: Halper Sadeh LLP Investigates LMNX, NUAN, CADE, GNMK; Shareholders are Encouraged to Contact the Firm

NEW YORK, April 12, 2021 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Luminex Corporation (NASDAQ: LMNX) and its board of directors concerning the proposed acquisition of the company by DiaSorin S.p.A. Stockholders will receive $37.00 for each share of Luminex stock that they hold.

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Luminex Corporation

Investors reacted favorably over the announcement that Saluggia, Italy-based DiaSorin SpA (MIL:DIA) is paying $1.8 billion to purchase Austin, Texas-based Luminex Corp. (NASDAQ:LMNX), a developer of proprietary biological testing technologies and products for the diagnostics, pharmaceutical and research industries worldwide. DiaSorin's shares gained about 9% to $182 on Monday.

Italian Diagnostic Developer Calls Luminex a 'Perfect Fit'

NEW YORK, April 12, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Luminex Corporation ("Luminex" or the "Company") (NASDAQ: LMNX) in connection with the proposed acquisition of the Company by Italian diagnostics group DiaSorin S.p.A. Under the terms of the merger agreement, the Company's shareholders will receive only $37.00 per share in cash for each share of Luminex common stock that they hold.

SHAREHOLDER ALERT: WeissLaw LLP Investigates Luminex Corporation

MILWAUKEE, April 12, 2021 /PRNewswire/ -- Ademi LLP is investigating Luminex (NASDAQ: LMNX) for possible breaches of fiduciary duty and other violations of law in its transaction with DiaSorin. Click here to learn how to join the action: https://www.ademilaw.com/case/luminex-corporation or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Luminex Corporation has obtained a Fair Price in its transaction with DiaSorin

SALUGGIA, Italy, April 11, 2021 /PRNewswire/ -- DiaSorin S.p.A. ("DiaSorin"; FTSE MIB: DIA) today announced that its Board of Directors has unanimously approved and signed a definitive merger agreement for DiaSorin to acquire Luminex Corporation ("Luminex"; NASDAQ: LMNX) for a price of USD 37.00 per share in an all-cash transaction.

DiaSorin to acquire Luminex Corporation for USD 37.00 per share or approximately USD 1.8 billion

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Luminex Corporation (NASDAQ: LMNX) to DiaSorin S.p.A. for $37.00 per share is fair to Luminex shareholders. Halper Sadeh encourages Luminex shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Luminex and its

Luminex Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Luminex Corporation Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – LMNX

The stock price of Luminex Corporation (NASDAQ: LMNX) increased by over 9% pre-market. This is why it happened.

LMNX Stock: Over 9% Increase Pre-Market Explanation

Shares of Italian diagnostic specialist DiaSorin surged 7% on Monday after announcing a deal to buy COVID-19 testing kit maker Luminex Corp. for around $1.8 billion. DiaSorin will pay $37 for each share of the U.S. company that develops, manufactures and sells proprietary biological testing technologies, it said in a press release on Sunday.

DiaSorin to acquire U.S.-based Luminex for around $1.8 billion

Investor confidence is high in Luminex (LMNX) stock, courtesy of its solid prospects.

Here's Why You Should Retain Luminex (LMNX) Stock for Now

Luminex (LMNX) develops the combined assay to rapidly deliver clear solutions about respiratory infections from a single test.

Luminex (LMNX) Files EUA Application for New Respiratory Assay

Luminex (LMNX) reported earnings 30 days ago. What's next for the stock?

Luminex (LMNX) Up 14.4% Since Last Earnings Report: Can It Continue?

AUSTIN, Texas, March 10, 2021 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has submitted an Emergency Use Authorization application to the U.S. Food and Drug Administration for the company's new multi-analyte respiratory panel combining Flu A/B and respiratory syncytial virus (RSV) targets with the SARS-CoV-2 target. The ARIES® Flu A/B & RSV+SARS-CoV-2 Assay can be run on all Luminex ARIES® Systems.

Luminex Submits Joint SARS-CoV-2 and Flu/RSV Respiratory Panel to FDA for Emergency Use Authorization

AUSTIN, Texas, March 9, 2021 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that Homi Shamir, Chairman, CEO & President, and Harriss Currie, Senior Vice President and CFO, plan to participate at the 2021 Barclays Global Healthcare Conference on March 10, 2021 at 8:35 a.m. Eastern Time.

Luminex Corporation to Participate at the 2021 Barclays Global Healthcare Conference

Luminex (LMNX) Surges 6.3%: Is This an Indication of Further Gains?

AUSTIN, Texas, March 4, 2021 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for a new expanded version of its NxTAG® Respiratory Pathogen Panel (RPP) that includes...

Luminex Receives FDA Emergency Use Authorization and CE Mark for Expanded NxTAG® Respiratory Panel Test Including SARS-CoV-2

Luminex Corporation (NASDAQ: LMNX) has received $11.3 million in funding from the Biomedical Advanced Research and Development Authority (BARDA). It will support the rapid development and validation of a respiratory panel combining Flu A/B & respiratory syncytial virus targets with the SARS-CoV-2 target that can run on all ARIES Systems.

Luminex Secures BARDA Funding To Develop And Validate Flu/COVID-19 Combo Respiratory Panel

AUSTIN, Texas, Feb. 19, 2021 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) today announced that it has received $11.3 million in funding from the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and...

Luminex Receives BARDA Funding to Support Development and Validation of Test Combining SARS-CoV-2 and Flu/RSV Respiratory Panel

Luminex (LMNX) witnesses total sample-to-answer molecular diagnostics revenue growth in the fourth quarter.

Luminex (LMNX) Q4 Earnings Miss Estimates, Revenues Beat

Luminex Corporation (LMNX) CEO Homi Shamir on Q4 2020 Results - Earnings Call Transcript

News for Luminex Stock (LMNX)